Immunopotentiating formulations for vaccinal use

The present invention is related to the field of medicine, particularly to the use of new adjuvant formulations with vaccine antigens. The technical objective pursued with this invention is, precisely, the development of formulations that are able to increase and/or modulate the immune response of t...

Full description

Saved in:
Bibliographic Details
Main Authors LUIS JAVIER CRUZ RICONDO, JULIO CESAR AGUILAR RUBIDO, JUAN JOEL MADRAZO PINOL, ENRIQUE IGLESIAS PEREZ, TANIA CARMENATE PORTILLA, CIRSE MESA PARDILLO, VERENA LUCILA MUZIO GONZALEV, EDUARDO PENTON ARIAS, DAGMARA PICHARDO DIAZ, MAYLIN DIAZ MARTINEZ, MARIA DE JESUS LEAL ANGULO, GERARDO ENRIQUE GUILLEN NIETO, GLORIA VELIZ RIOS, ANTONIETA HERRERA BUCH, MAYDEL HECHAVARRIA GAY
Format Patent
LanguageEnglish
Published 22.12.2000
Edition7
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention is related to the field of medicine, particularly to the use of new adjuvant formulations with vaccine antigens. The technical objective pursued with this invention is, precisely, the development of formulations that are able to increase and/or modulate the immune response of the organism to vaccine antigens in the serum and the mucous lining. With this aim, a formulation was developed that contained as the main components the surface antigen of the hepatitis B virus and the acemannan in adequate proportions. As an extension of this result, formulations were developed in which a) HBsAg was used as the homologous or heterologous antigen carrier b) delivery systems of particulated antigens and c) soluble antigens, combined with the acemannan in specific proportions. The formulations of this invention are applicable in the pharmaceutical industry as vaccine formulations for human and veterinary use.
Bibliography:Application Number: HK20000105771